SBFM - Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs
- Sunshine Biopharma is developing novel Topoisomerase II inhibiting cancer therapies and PLpro inhibiting antiviral drugs.
- The Company has a strong IP backing, although much of it is tied in with the CEO.
- The Company recently raised $13.6 million in net proceeds from a public offering following a 200:1 reverse split, and a private placement.
- Note: we do not recommend stocks with such low market caps however attractive they may otherwise sound.
For further details see:
Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs